Glioblastoma (GBM) is the most aggressive primary brain tumour. As GBM incidence is associated with age, elderly people represent a consistent subgroup of patients. Elderly people with GBM show dismal prognosis (about 6 months) and limited response to treatments. Age is a negative prognostic factor, which correlates with clinical frailty, poorer tolerability to surgery or adjuvant radio‐chemotherapy, and higher occurrence of comorbidities and/or secondary complications. The aim of this paper is to review the clinical and molecular characteristics, current therapeutic options, and prognostic factors of elderly patients with GBM.
Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects
Bruno, Francesco
First
;Pellerino, Alessia;Bertero, Luca;Mantovani, Cristina;Garbossa, Diego;Soffietti, Riccardo;Ruda, RobertaLast
2022-01-01
Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumour. As GBM incidence is associated with age, elderly people represent a consistent subgroup of patients. Elderly people with GBM show dismal prognosis (about 6 months) and limited response to treatments. Age is a negative prognostic factor, which correlates with clinical frailty, poorer tolerability to surgery or adjuvant radio‐chemotherapy, and higher occurrence of comorbidities and/or secondary complications. The aim of this paper is to review the clinical and molecular characteristics, current therapeutic options, and prognostic factors of elderly patients with GBM.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Glioblastoma in the elderly.pdf
Accesso aperto
Descrizione: Articolo
Tipo di file:
PDF EDITORIALE
Dimensione
580.89 kB
Formato
Adobe PDF
|
580.89 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
